SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
ajt12313-sm-0001-SupFig-S1.eps32K

Figure S1: Steroid dose at posttransplant year 5 according to steroid dose at year 1 and the proportion of patients in whom steroids were withdrawn during posttransplant years 2–5.

ajt12313-sm-0001-SupFig-S2.eps42K

Figure S2: Death with a functioning graft during years 2–5 in recipients who were steroid-free at year 1 posttransplant according to whether they initially after transplantation were placed on steroids or not.

ajt12313-sm-0001-SupFig-S3.eps73K

Figure S3: Death with a functioning graft during years 2–5 in recipients with original disease (A) diabetic nephropathy, (B) hypertensive nephropathy or (C) polycystic kidney disease according to steroid dose (mg/kg/day) at year 1 posttransplant.

ajt12313-sm-0001-SupData.doc78K

Table S1: Significant confounders (excluding dosage of steroids or other immunosuppressants) included in the Cox regression analysis of cumulative incidence of death with a functioning graft due to cardiovascular disease or infection during posttransplant years 2–5 (n = 41 953).

Table S2: Results of Cox regression for death with functioning graft during posttransplant years 2 to 5 according to 1-year steroid dose.

Table S3: De novo occurrence during posttransplant years 2–5. Patients with serum creatinine <130 µmol/L at year 1 and no rejection treatment during year 1.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.